Increased clopidogrel response is associated with ABCC3 expression: A pilot study


Autoria(s): Luchessi, Andre Ducati; Silbiger, Vivian Nogueira; Cerda, Alvaro; Hirata, Rosario Dominguez Crespo; Carracedo, Angel; Brion, Maria; Iniguez, Andres; Bravo, Marisol; Bastos, Guillermo; Sousa, Amanda Guerra Morais Rego; Hirata, Mario Hiroyuki
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

24/09/2013

24/09/2013

01/02/2012

Resumo

Background: The aim of this study was investigate the relationship between ABCB1 and ABCC3 gene expressions in peripheral blood cells (PBC) and the response to clopidogrel in patients with coronary arterial disease (CAD). Methods: Twenty-six male CAD patients (50-70 years) under treatment with clopidogrel (75 mg/day) for at least 5 days were selected. Blood samples were obtained to evaluate platelet reactivity and ABCB1 and ABCC3 mRNA expression. Platelet reactivity was measured in P2Y12 Reaction Units (PRU) using VerifyNow. RNA was extracted from PBC and mRNA levels were measured by qPCR, using GAPD as a reference gene. Results: Platelet response to clopidogrel was categorized in to PRU quartiles. Individuals with PRU values within the first quartile (Q1, <151 units) were considered good responders, while those who had PRU within the fourth quartile (Q4. PRU>260) were considered non-responders. ABCC3 was 1.7 times more expressed in Q4 than in Q1 PRU group (p=0.048). Moreover, CAD patients with low ABCC3 expression (Qe1, <2.5x10(-3)) had higher probability to have a good response to clopidogrel (OR: 18.00, 95%CI: 1.90-169.99, p=0.001). Univariate linear regression analysis demonstrated that low ABCC3 mRNA expression contributed with a reduction of 73 PRU in relation to the patients with expression value higher than 2.5x10(-3) (p=0.027). Neither ABCB1 mRNA levels nor clinical variables studied influenced PRU values. Conclusions: Low ABCC3 mRNA expression in peripheral blood cells is associated with increased clopidogrel response, but further studies are needed to describe the functional relationship of clopidogrel with the ABCC3. Crown Copyright (C) 2011 Published by Elsevier B.V. All rights reserved.

FAPESP-Brazil [2006/03487-4]

FAPESP (Brazil)

Spanish Health Institute ISCIII

Spanish Health Institute ISCIII [EMER07/018]

DIANA of the Fundacion Pedro Barrie de la Maza-Spain

DIANA of the Fundacion Pedro Barrie de la MazaSpain

CNPq-Brazil

CNPq (Brazil)

CONICYT, Chile

CONICYT-Chile

Identificador

CLINICA CHIMICA ACTA, AMSTERDAM, v. 413, n. 41367, pp. 417-421, FEB 18, 2012

0009-8981

http://www.producao.usp.br/handle/BDPI/33651

10.1016/j.cca.2011.10.018

http://dx.doi.org/10.1016/j.cca.2011.10.018

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE BV

AMSTERDAM

Relação

CLINICA CHIMICA ACTA

Direitos

openAccess

Copyright ELSEVIER SCIENCE BV

Palavras-Chave #ABCC3 #ABCB1 #PHARMACOGENOMICS #CLOPIDOGREL #ANTIPLATELET AGENTS #BLOOD MONONUCLEAR-CELLS #DRUG TRANSPORTERS #P-GLYCOPROTEIN #RESISTANCE #CORONARY #POLYMORPHISMS #ATORVASTATIN #DISEASE #GENE #PHARMACOTHERAPY #MEDICAL LABORATORY TECHNOLOGY
Tipo

article

original article

publishedVersion